Antibody-drug conjugate · Cytotoxic, directed at KAAG1 · developed by ADC Therapeutics
Olintatug tesirine is an antibody-drug conjugate composed of a humanized anti-KAAG1 antibody conjugated to SG3199, a pyrrolobenzodiazepine dimer. The antibody binds KAAG1 on cancer cells; upon internalization and cathepsin cleavage, the cytotoxic payload forms DNA interstrand cross-links, killing KAAG1-expressing tumor cells. It is studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04972981 | Phase 1 | Advanced Solid Tumors | Completed | ADCT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumors
See ADCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ADCT catalysts and pipeline →